Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T6IN
|
|||
| Former ID |
DIB008293
|
|||
| Drug Name |
Peginterferon lambda-1a
|
|||
| Synonyms |
BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb
Click to Show/Hide
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 3 | [1] | |
| Company |
Bristol-myers squibb
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-29 (IL29) | Target Info | Agonist | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| WikiPathways | Type III interferon signaling | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01866930) Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naive Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV. U.S. National Institutes of Health. | |||
| REF 2 | Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res. 2010 Aug;30(8):591-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.